News &amp; Updates

Inotuzumab ozogamicin is well tolerated and demonstrates clinical activity in children with relapsed or refractory acute lymphoblastic leukaemia (ALL), according to the results of a phase II trial.

Inotuzumab ozogamicin safe, effective in relapsed, refractory paediatric ALL

Novel targeted therapy shows better response than chemo in BRAF V600-mutant paediatric LGG

05 Jul 2022 by

The combination of two targeted therapies, dabrafenib and trametinib, significantly improves the overall response rate (ORR) in paediatric patients with low-grade glioma (LGG) with BRAF V600 mutations compared with the combination of standard chemotherapy drugs, according to a study presented at ASCO 2022.

Novel targeted therapy shows better response than chemo in BRAF V600-mutant paediatric LGG

Adagrasib promising in KRASG12C-mutated NSCLC

05 Jul 2022 by

The KRAS^G12C inhibitor adagrasib shows durable clinical benefit, without new safety signals, in pretreated patients with advanced non–small cell lung cancer (NSCLC) harbouring a KRAS^G12C mutation in the KRYSTAL-1 trial.

Adagrasib promising in KRASG12C-mutated NSCLC

TNFi use carries only modest increase in psoriasis risk

04 Jul 2022 by

The use of tumour necrosis factor-α inhibitor (TNFi) for inflammatory bowel disease (IBD) or rheumatoid arthritis (RA) raises the risk of developing psoriasis by twofold as compared with conventional therapy, although the absolute risk remains modest, as reported in a study.

TNFi use carries only modest increase in psoriasis risk

04 Jul 2022

Statins reduce death, mechanical ventilation use in hospitalized COVID-19 patients

04 Jul 2022 by

Hospitalized patients with COVID-19 who are treated with statins are less likely to undergo invasive mechanical ventilation or die, according to the results of a multicentre study in the US.

Statins reduce death, mechanical ventilation use in hospitalized COVID-19 patients

04 Jul 2022

Starting 2.5-mg tPA/5-mg DNase dose effective in patients with pleural infection

Use of 2.5-mg tissue plasminogen activator (tPA) and 5-mg deoxyribonuclease (DNase) therapy as a starting intrapleural dose, with up-titration if needed, appears effective in patients with pleural infection, suggests a study, noting that this treatment warrants further research.

Starting 2.5-mg tPA/5-mg DNase dose effective in patients with pleural infection

Tenofovir alafenamide easy on CHB patients with renal, bone mineral density problems

In chronic hepatitis B (CHB) patients with renal and/or bone mineral density disorders or risks, treatment with tenofovir alafenamide (TAF) leads to improvements in estimated glomerular filtration rate (eGFR) after 12–24 months, especially for patients with low eGFR levels at baseline, while maintaining virological suppression, according to data from HERACLIS-TAF.

Tenofovir alafenamide easy on CHB patients with renal, bone mineral density problems

Second-line antiseizure drug helps with toxin-related seizure in status epilepticus patients

Some patients with benzodiazepine-refractory status epilepticus experience a toxin-related seizure, which can be successfully treated with a single dose of second-line antiseizure medication, according to a post hoc analysis of the Established Status Epilepticus Treatment Trial (ESETT).

Second-line antiseizure drug helps with toxin-related seizure in status epilepticus patients

Immediate-release rifaximin may prevent complications, boost recovery in cirrhotic patients with OHE

Rifaximin soluble solid dispersion immediate-release tablet has the potential to reduce hospitalization in patients with cirrhosis and promote the resolution of overt hepatic encephalopathy (OHE) during hospitalization, according to analyses of two phase II trials.

Immediate-release rifaximin may prevent complications, boost recovery in cirrhotic patients with OHE

Gout patients endorse reasons for not taking allopurinol